Renal Toxicity of Adjuvant Chemoradiotherapy With Cisplatin in Gastric Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 69, Issue 5, 2007, Pages 1429-1435

  Welz, Stefan ^a   Hehr, Thomas ^a,d   Kollmannsberger, Christian ^b   Bokemeyer, Carsten ^c   Belka, Claus ^d   Budach, Wilfried ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF HAMBURG   (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Cisplatin; Gastric cancer; Radiotherapy; Renal; Toxicity

Indexed keywords

BIOLOGICAL ORGANS; ONCOLOGY; RISK MANAGEMENT; TOXICITY;

CISPLATIN; GASTRIC CANCER;

RADIOTHERAPY;

CISPLATIN; CREATININE; FLUOROURACIL; FOLINIC ACID; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CREATININE CLEARANCE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; KIDNEY FUNCTION; KIDNEY TUBULE ABSORPTION; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; STOMACH ADENOCARCINOMA; STOMACH CANCER; TREATMENT OUTCOME;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CREATININE; ESOPHAGOGASTRIC JUNCTION; FEMALE; FLUOROURACIL; HUMANS; KIDNEY; LEUCOVORIN; MALE; MIDDLE AGED; PACLITAXEL; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; STOMACH NEOPLASMS;

EID: 36148976443     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.05.021     Document Type: Article

References (13)

1. Macdonald J.S., Smalley S.R., Benedetti J., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345 (2001) 725-730
2. Kollmannsberger C., Budach W., Stahl M., et al. Adjuvant chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: Two cooperative phase II studies of the AIO/ARO/ACO. Ann Oncol 16 (2005) 1326-1333
3. Emami B., Lyman J., Brown A., et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21 (1991) 109-122
4. Stewart F.A., Oussoren Y., and Bartelink H. The influence of cisplatin on the response of mouse kidneys to multifraction irradiation. Radiother Oncol 15 (1989) 93-102
5. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
6. DuBois D., and DuBois E.F. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 17 (1916) 863
7. Igaki H., Karasawa K., Sakamaki H., et al. Renal dysfunction after total-body irradiation: Significance of selective renal shielding blocks. Strahlenther Onkol 181 (2005) 704-708
8. van Kleef E.M., Zurcher C., Oussoren Y.G., et al. Long-term effects of total-body irradiation on the kidney of rhesus monkeys. Int J Radiat Biol 76 (2000) 641-648
9. Safwat A., Bentzen S.M., Nielsen O.S., et al. Time-course of the hazard of murine nephropathy induced by total-body irradiation. Int J Radiat Biol 76 (2000) 979-983
10. Trott K.R., Herrmann T., and Dörr W. Strahlenwirkung auf Normalgewebe (2002), Urban and Vogel, Munich p. 53-55
11. Lawton C.A., Cohen E.P., Murray K.J., et al. Long-term results of selective renal shielding in patients undergoing total body irradiation in preparation for bone marrow transplantation. Bone Marrow Transplant 20 (1997) 1069-1074
12. Miralbell R., Sancho G., Bieri S., et al. Renal insufficiency in patients with hematologic malignancies undergoing total body irradiation and bone marrow transplantation: A prospective assessment. Int J Radiat Oncol Biol Phys 58 (2004) 809-816
13. Down J.D., Berman A.J., Warhol M., et al. Late complications following total-body irradiation and bone marrow rescue in mice: Predominance of glomerular nephropathy and hemolytic anemia. Int J Radiat Biol 57 (1990) 551-565